Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)

European Heart Journal

Volumn 33, Issue 18, 2012, Pages 2290-2296

  Gullestad, Lars ^a,b   Ueland, Thor ^a,b   Kjekshus, John ^a,b   Nymo, Ståle H ^a,b   Hulthe, Johannes ^c,d   Muntendam, Pieter ^e   Adourian, Aram ^e   Böhm, Michael ^f   Van Veldhuisen, Dirk J ^g   Komajda, Michel ^h   Cleland, John G F ⁱ   Wikstrand, John ^c   McMurray, John J V ^j   Aukrust, Pål ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d ASTRAZENECA R AND D   (Sweden)

^e BG Medicine Inc   (United States)

^f SAARLAND UNIVERSITY   (Germany)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ CASTLE HILL HOSPITAL   (United Kingdom)

^j UNIVERSITY OF GLASGOW   (United Kingdom)

more..

Author keywords

Atherosclerosis; Cardiovascular pharmacology; Heart failure; Lipids; Statins

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GALECTIN 3; LOOP DIURETIC AGENT; ROSUVASTATIN;

ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; MORTALITY; PRIORITY JOURNAL; SERUM; STROKE; SYSTOLE; TREATMENT RESPONSE;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; FLUOROBENZENES; GALECTIN 3; HEART FAILURE, SYSTOLIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIER ESTIMATE; LIPID METABOLISM; MALE; MYOCARDIAL INFARCTION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PYRIMIDINES; STROKE; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84866430394     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs077     Document Type: Article

References (16)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease: the Scandinavian Simvas-tatin Survival Study (4S). Lancet 1995;344:1383-1389.
2. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of cholesterol levels. N Engl J Med 1998;339:1349-1357.
3. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvas-tatin on the incidence of heart failure in patients with coronary heart disease [see comment] [erratum appears in J Card Fail 1998;4:367]. J Card Fail 1997;3:249-254. (Pubitemid 127674856)
4. Raina A, Pickering T, Shimbo D. Statin use in heart failure: a cause for concern? (Review). Am Heart J 2006;152:39-44.
5. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Janosi A, Kamensky G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J, CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-2261. (Pubitemid 350190755)
6. Gissi-HF I, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1231-1239.
7. Cleland JG, McMurray JJ, Kjekshus J, Cornel JH, Dunselman P, Fonseca C, Hjalmarson A, Korewicki J, Lindberg M, Ranjith N, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J, CORONA Study Group. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol 2009;54:1850-1859.
8. McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamensky G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J, CORONA Study Group. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation 2009;120:2188-2196.
9. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, Andre S, Crijns HJ, Gabius HJ, Maessen J, Pinto YM. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004;110:3121-3128. (Pubitemid 39492008)
10. Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, Liu FT, Hughes J, Sethi T. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008;172:288-298. (Pubitemid 351282017)
11. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP, Pinto YM. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006;48:1217-1222.
12. Lok DJA, Van Der Mer P, de la Porta PW-A, Lipsic E, Hillege HL, van Veldhuisen DJ. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010;99:323-328.
13. de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ. Galectin-3: a novel mediator of heart failure development and progression. (Review). Eur J Heart Fail 2009;11:811-817.
14. Ueland T, Aukrust P, Broch K, Aakhus S, Skardal R, Muntendam P, Gullestad L. Galectin-3 in heart failure: high levels are associated with all cause mortality. Int J Cardiol 2011;150:361-364.
15. Wedel H, McMurray JJ, Lindberg M, Wikstrand J, Cleland JGF, Cornel JH, Dunselman P, Hjalmarson A, Kjekshus J, Komajda M, Kuusi T, Vanhaecke J, Waagstein F. Predictors of fatal and non-fatal outcomes in the Controlled Rosu-vastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail 2009;11:281-291.
16. Kwak B, Mulhaup F, Mylt S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000;6:1399-1402. (Pubitemid 32001026)